These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 16460675)
1. The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Zhang J; Xu J; Li G; Dong D; Song X; Guo Q; Zhao J; Fu L; Chen W Biochem Biophys Res Commun; 2006 Mar; 341(4):1164-71. PubMed ID: 16460675 [TBL] [Abstract][Full Text] [Related]
2. [Toxin-neutralizing monoclonal antibodies to the different domains of anthrax protective antigen]. Xu JJ; Zhang J; Liu SL; Lv TJ; Chen W; Li GL; Ge M; Guo Q Wei Sheng Wu Xue Bao; 2005 Dec; 45(6):947-51. PubMed ID: 16496709 [TBL] [Abstract][Full Text] [Related]
3. The inhibition of the interaction between the anthrax toxin and its cellular receptor by an anti-receptor monoclonal antibody. Li G; Qu Y; Cai C; Kong Y; Liu S; Zhang J; Zhao J; Fu L; Xu J; Chen W Biochem Biophys Res Commun; 2009 Aug; 385(4):591-5. PubMed ID: 19486894 [TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis. Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802 [TBL] [Abstract][Full Text] [Related]
5. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine. Yin Y; Zhang S; Cai C; Zhang J; Dong D; Guo Q; Fu L; Xu J; Chen W Immunobiology; 2014 Feb; 219(2):97-103. PubMed ID: 24054942 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis. Rhie GE; Park YM; Han JS; Yu JY; Seong WK; Oh HB FEMS Immunol Med Microbiol; 2005 Aug; 45(2):341-7. PubMed ID: 16019195 [TBL] [Abstract][Full Text] [Related]
7. Identification of new dominant-negative mutants of anthrax protective antigen using directed evolution. Wu G; Feng C; Cao S; Guo A; Liu Z Appl Biochem Biotechnol; 2012 Nov; 168(5):1302-10. PubMed ID: 22948605 [TBL] [Abstract][Full Text] [Related]
8. Mapping of antibody responses to the protective antigen of Bacillus anthracis by flow cytometric analysis. Reed DS; Smoll J; Gibbs P; Little SF Cytometry; 2002 Sep; 49(1):1-7. PubMed ID: 12210604 [TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibodies to B.anthracis protective antigen are capable to neutralize and to enhance the anthrax lethal toxin action in vitro]. Belova EV; Dubileĭ SA; Kravchenko TB; Kolesnikov AV; Zakharova MIu; Shemiakin IG Mol Gen Mikrobiol Virusol; 2004; (3):21-6. PubMed ID: 15354937 [TBL] [Abstract][Full Text] [Related]
10. Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C. Wu G; Feng C; Hong Y; Guo A; Cao S; Dong J; Lin L; Liu Z Appl Microbiol Biotechnol; 2010 Jun; 87(2):609-16. PubMed ID: 20213183 [TBL] [Abstract][Full Text] [Related]
11. Catalytically inactive anthrax toxin(s) are potential prophylactic agents. Gupta M; Alam S; Bhatnagar R Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo. Little SF; Webster WM; Fisher DE FEMS Immunol Med Microbiol; 2011 Jun; 62(1):11-22. PubMed ID: 21231965 [TBL] [Abstract][Full Text] [Related]
13. A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion. Mechaly A; Levy H; Epstein E; Rosenfeld R; Marcus H; Ben-Arie E; Shafferman A; Ordentlich A; Mazor O J Biol Chem; 2012 Sep; 287(39):32665-73. PubMed ID: 22869370 [TBL] [Abstract][Full Text] [Related]
14. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses. Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249 [TBL] [Abstract][Full Text] [Related]
15. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. Yan M; Roehrl MH; Basar E; Wang JY Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092 [TBL] [Abstract][Full Text] [Related]
16. Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies. Abboud N; De Jesus M; Nakouzi A; Cordero RJ; Pujato M; Fiser A; Rivera J; Casadevall A J Biol Chem; 2009 Sep; 284(37):25077-86. PubMed ID: 19617628 [TBL] [Abstract][Full Text] [Related]
17. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine. Gubbins MJ; Schmidt L; Tsang RS; Berry JD; Kabani A; Stewart DI J Immunoassay Immunochem; 2007; 28(3):213-25. PubMed ID: 17613668 [TBL] [Abstract][Full Text] [Related]